Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED Levbid ® (hyoscyamine sulfate 0.375 mg) extended-release tablets are white, capsule-shaped tablets. They are coded AP on one side and 115 on the other. Bottles of 100 NDC 68220-115-10 Store at controlled room temperature 20°-25°C (68°- 77°F); brief excursions permitted to 15°-30°C (59°- 86°F). Please refer to current USP. Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure. KEEP OUT OF REACH OF CHILDREN Also available as: Levsin ® dosage strength package size NDC Sublingual Tablets 0.125 mg 100’s 68220-113-10 Tablets 0.125 mg 100’s 68220-112-10 For more information, call Viatris at 1-877-446-3679 (1-877-4-INFO-RX). LEVBID is a registered trademark of Alaven Pharmaceutical LLC, a Viatris Company. © 2025 Viatris Inc. Distributed by: Viatris Specialty LLC Morgantown, WV 26505 U.S.A. 201090-01 115 Rev. 07/2025 VS:SOV:LVBDER:R1; PRINCIPAL DISPLAY PANEL – 0.375 MG NDC 68220- 115 -10 Levbid ® extended-release tablets (hyoscyamine sulfate, 0.375 mg) Rx only 100 tablets USUAL DOSAGE: Adults and pediatric patients 12 years of age and older: 1 to 2 tablets every 12 hours. See package insert for further information. Store at controlled room temperature 20°- 25°C (68° - 77°F); brief excursions permitted to 15°- 30°C (59°- 86°F). Please refer to current USP. Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure. Distributed by: Viatris Specialty LLC Morgantown, WV 26505 U.S.A. LEVBID is a registered trademark of Alaven Pharmaceutical LLC, a Viatris Company. © 2025 Viatris Inc. VSSOV115A1 200950-01 Rev 06/2025 Levbid Extended-Release Tablets 0.375 mg Bottle Label
- HOW SUPPLIED Levbid ® (hyoscyamine sulfate 0.375 mg) extended-release tablets are white, capsule-shaped tablets. They are coded AP on one side and 115 on the other. Bottles of 100 NDC 68220-115-10 Store at controlled room temperature 20°-25°C (68°- 77°F); brief excursions permitted to 15°-30°C (59°- 86°F). Please refer to current USP. Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure. KEEP OUT OF REACH OF CHILDREN Also available as: Levsin ® dosage strength package size NDC Sublingual Tablets 0.125 mg 100’s 68220-113-10 Tablets 0.125 mg 100’s 68220-112-10 For more information, call Viatris at 1-877-446-3679 (1-877-4-INFO-RX). LEVBID is a registered trademark of Alaven Pharmaceutical LLC, a Viatris Company. © 2025 Viatris Inc. Distributed by: Viatris Specialty LLC Morgantown, WV 26505 U.S.A. 201090-01 115 Rev. 07/2025 VS:SOV:LVBDER:R1
- PRINCIPAL DISPLAY PANEL – 0.375 MG NDC 68220- 115 -10 Levbid ® extended-release tablets (hyoscyamine sulfate, 0.375 mg) Rx only 100 tablets USUAL DOSAGE: Adults and pediatric patients 12 years of age and older: 1 to 2 tablets every 12 hours. See package insert for further information. Store at controlled room temperature 20°- 25°C (68° - 77°F); brief excursions permitted to 15°- 30°C (59°- 86°F). Please refer to current USP. Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure. Distributed by: Viatris Specialty LLC Morgantown, WV 26505 U.S.A. LEVBID is a registered trademark of Alaven Pharmaceutical LLC, a Viatris Company. © 2025 Viatris Inc. VSSOV115A1 200950-01 Rev 06/2025 Levbid Extended-Release Tablets 0.375 mg Bottle Label
Overview
Levbid ® extended-release tablets contain 0.375 mg of hyoscyamine sulfate in a formulation designed for oral b.i.d. dosage. Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The empirical formula is (C 17 H 23 NO 3 )2•H 2 SO 4 •2H 2 O and the molecular weight is 712.85. Chemically, it is benzeneacetic acid, α-(hydroxymethyl)-,8-methyl-8-azabicyclo [3.2.1.] oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate with the following structure: Each Levbid ® extended-release tablet also contains as inactive ingredients: calcium phosphate dibasic, ethylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and stearic acid. chemical structure
Indications & Usage
Levbid ® is effective as adjunctive therapy in the treatment of peptic ulcer. It can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Levbid ® is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a “drying agent” in the relief of symptoms of acute rhinitis; in the therapy of Parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.
Dosage & Administration
Dosage may be adjusted according to the conditions and severity of symptoms. Adults and pediatric patients 12 years of age and older: 1 to 2 tablets every 12 hours. Do not crush or chew tablets. Do not exceed 4 tablets in 24 hours.
Warnings & Precautions
WARNINGS In the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. Like other anticholinergic agents, Levbid ® may produce drowsiness, dizziness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug. Psychosis has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate. CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, euphoria, anxiety, fatigue, insomnia, agitation and mannerisms, and inappropriate affect. These CNS signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug.
Contraindications
Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
Adverse Reactions
All of the following adverse reactions have been reported with hyoscyamine sulfate. Adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; fatigue; dizziness; insomnia; nausea; vomiting; impotence; constipation; bloated feeling; abdominal pain; diarrhea; allergic reactions or drug idiosyncrasies; urticaria and other dermal manifestations; ataxia; speech disturbance; some degree of mental confusion and/or excitement (especially in elderly persons); short-term memory loss; hallucinations; and decreased sweating.
Drug Interactions
Additive adverse effects resulting from cholinergic blockade may occur when Levbid ® is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines. Antacids may interfere with the absorption of Levbid ® .
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.